New Delhi: Johnson & Johnson (J & J) has applied to India’s Central Drugs Standard Control Organisation (CDSCO) for permission to conduct a study of its COVID vaccine Janssen among adolescents in this country aged 12-17 years.
In Phase 3 human clinical trials, the single-shot vaccine showed 85 per cent effective in preventing severe disease.
“Johnson & Johnson is committed to facilitating global equitable access to its COVID-19 vaccine and recognize the unmet needs of children. On August 17, 2021, we submitted an application to the Central Drugs Standard Control Organisation (CDSCO) to conduct a study of the Johnson & Johnson COVID-19 vaccine in India in adolescents aged 12-17 years,” Mirror Now quoted a Johnson & Johnson India spokesperson as saying.
“To ultimately achieve herd immunity, it is imperative that COVID-19 vaccine clinical trials continue to move forward in this population, and we remain deeply committed to the critical work needed to make our COVID-19 vaccine equitably accessible for all age groups,” he added.
The Drug Controller General of India has already granted J & J’s vaccine emergency use authorisation.
Once the J & J vaccine is cleared for the 12-17 age group, it will become the second one after Zudus Cadilla vaccine for young adolescents.
Also Read: Zydus Cadila’s 3-Dose Needle-Free Vaccine For Above 12 Gets Emergency Use Approval
